Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
TOKYO, March 10, 2026 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will…
